M. Galvin
Nature Biotechnology · 2005–2008
A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from M. Galvin's perspective
Ordered by how strongly the researchers M. Galvin trusts endorse each paper. Same corpus, a different order for every researcher.
- The specificities of protein kinase inhibitors: an update. (Biochemical Journal)
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
- Methods of Enzymatic Analysis
- The Protein Kinase Complement of the Human Genome (Science)
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. (Cancer Cell)
- High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who… (Blood)
- Integrating physiology and life history to improve fisheries management and conservation
- Protein kinases — the major drug targets of the twenty-first century? (Nature reviews. Drug discovery)
- Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. (Cell)
- Specificity and mechanism of action of some commonly used protein kinase inhibitors. (Biochemical Journal)